Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Neurol Sci ; 40(7): 1453-1455, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30778879

ABSTRACT

Pompe disease is a metabolic myopathy, due to deficiency of alpha glucosidase, with a wide clinical spectrum. Enzyme replacement therapy is the only available treatment to improve morbidity and mortality, especially in infantile-onset form. However, some patients experience infusion-associated reactions, which may restrict their access to this treatment. We report on two patients (respectively 12 and 3 months old) with infantile-onset Pompe disease and severe cardiomyopathy, that presented with severe reactions during infusion of enzyme replacement therapy and were successfully desensitized with a new individualized protocol. Our protocol, using microdilution and a premedication with antihistamines, corticosteroids, and tranexamic acid, seems safe and effective and it may allow the continuation of therapy in Pompe patients resulting in the reduction of morbidity and mortality related to this disease.


Subject(s)
Glycogen Storage Disease Type II/therapy , Hormone Replacement Therapy/methods , alpha-Glucosidases/administration & dosage , alpha-Glucosidases/adverse effects , Desensitization, Immunologic , Glycogen Storage Disease Type II/enzymology , Glycogen Storage Disease Type II/immunology , Humans , Infant , Male
2.
BMC Cardiovasc Disord ; 16(1): 243, 2016 11 29.
Article in English | MEDLINE | ID: mdl-27894269

ABSTRACT

BACKGROUND: Recent meta-analyses suggested that screening program for abdominal aortic aneurysms (AAA) in 65-year old males is cost-effective at prevalence of about 1%. Since some events occur also in females and among the youngers, screening could be feasible among those at higher risk, such as smokers or individuals with a family history of AAA. The RoCAV (Risk of Cardiovascular diseases and abdominal aortic Aneurysms in Varese) Project is a population-based study aimed to evaluate AAA prevalence in Northern Italy in males over-65 years as well as among females and younger males, and to identify new markers for risk stratification by collecting a large set of CVD risk factors. The aims of the project are: (i) cross-sectional evaluation of AAA prevalence (ii); evaluation of standard CVD risk score as criteria for selecting subgroup at higher risk to be included in a screening program; (iii) identification of new risk markers and risk score algorithm for AAA and CVD risk stratification; (iv) cost-effective evaluation during the follow-up. METHODS: Males aged 50-75 years and females aged 60-75 years, resident in the city of Varese (Lombardy Region), were randomly selected from the civil registry. Among 5198 successfully invited, 3777 subjects accepted to participate and were finally recruited (participation rate 63.8%) from June 2013 to May 2016. Trained operators administered a computerized anamnestic questionnaire, measured anthropometric parameters (BMI, body circumferences, skinfolds), blood pressure, ankle-brachial index, pulse wave velocity and performed abdominal aortic ultrasound scan, ECG and spirometry. All methods were internationally validated. A blood sample was collected and stored in biobank. A follow-up will be carried out through linkage with electronic records. DISCUSSION: Participation rate and data quality assessment were as expected and will reasonably allow to reach the project aims. The expected impact in public health of the RoCAV project will be the potential implementation of a AAA screening program to the whole region as well as the formulation of new criteria for risk assessment of AAA and CVD.


Subject(s)
Aortic Aneurysm, Abdominal/epidemiology , Population Surveillance/methods , Public Health , Risk Assessment/methods , Age Distribution , Aged , Aortic Aneurysm, Abdominal/diagnosis , Cardiovascular Diseases/epidemiology , Electrocardiography , Female , Humans , Italy/epidemiology , Male , Middle Aged , Prevalence , Retrospective Studies , Risk Factors , Sex Distribution , Spirometry , Ultrasonography
3.
Proc Natl Acad Sci U S A ; 93(15): 7821-5, 1996 Jul 23.
Article in English | MEDLINE | ID: mdl-8755560

ABSTRACT

To investigate the contribution of interleukin-4 (IL-4) to airway inflammation in vivo and to explore directly its relationship to airway reactivity, we created transgenic mice in which the murine cDNA for IL-4 was regulated by the rat Clara cell 10 protein promoter. Expression was detected only in the lung and not in thymus, heart, liver, spleen, kidney, or uterus. The expression of IL-4 elicited hypertrophy of epithelial cells of the trachea, bronchi, and bronchioles. Hypertrophy is due, at least in part, to the accumulation of mucus glycoprotein. Histologic examination of parenchyma revealed multinucleated macrophages and occasional islands of cells consisting largely of eosinophils or lymphocytes. Analysis of lung lavage fluid revealed the presence of a leukocytic infiltrate consisting of lymphocytes, neutrophils and eosinophils. Mice expressing IL-4 had greater baseline airway resistance but did not demonstrate hyperreactivity to methacholine. Thus, the expression of IL-4 selectively within the lung elicits an inflammatory response characterized by epithelial cell hypertrophy, and the accumulation of macrophages, lymphocytes, eosinophils, and neutrophils without resulting in an alteration in airway reactivity to inhaled methacholine.


Subject(s)
Eosinophils/immunology , Interleukin-4/biosynthesis , Interleukin-4/genetics , Lung/immunology , Lymphocytes/immunology , Transcription, Genetic , Animals , Bronchoalveolar Lavage Fluid/immunology , DNA, Complementary , Eosinophils/pathology , Female , Hypertrophy , Inflammation , Interleukin-4/blood , Lung/pathology , Lymphocytes/pathology , Mice , Mice, Transgenic , Organ Specificity , Phenotype , Promoter Regions, Genetic , RNA, Messenger/biosynthesis , Rats , Restriction Mapping
SELECTION OF CITATIONS
SEARCH DETAIL
...